WATCHAF: SmartWATCHes for Detection of Atrial Fibrillation

Sponsor
University Hospital, Basel, Switzerland (Other)
Overall Status
Completed
CT.gov ID
NCT02956343
Collaborator
University Hospital Greifswald (Other)
651
2
12
325.5
27.1

Study Details

Study Description

Brief Summary

In this trial the Preventives Heartbeats algorithm will be tested in two wearable devices for its specificity and sensitivity to distinguish between AF and SR.

Condition or Disease Intervention/Treatment Phase
  • Device: Five minutes pulse wave recording

Detailed Description

Introduction

Particularly in stroke prevention, the detection of atrial fibrillation is of pivotal importance. Recent studies have impressively confirmed the merits of long-term monitoring. Nevertheless, and despite very mature technology, the currently available methods like long-term ECG with conductive adhesive electrodes or implantable loop recorders are burdened with disadvantages in that they are inconvenient, costly and/or invasive. A predecessor study gave us the possibility to test an app that employs photoplethysmographic signals on a smartphone camera-similar to pulse oximetry technology-to distinguish between atrial fibrillation and sinus rhythm. That retrospective study achieved a sensitivity and specificity of 95% (Krivoshei et al., Europace 2016). The prospective follow-up study DETECT AF pro is currently being conducted in cooperation with Prof. Dörr in Greifswald, Germany.

Our research group has been involved with testing the app's quality in clinical settings before implementing it for use. This procedure differs markedly from the otherwise common practice of marketing qualitatively inferior "health apps" without any clinical testing. There is no app equipped with comparable technology worldwide. The WATCH AF study is the first study on sophisticated rhythm analysis using a smartwatch worldwide.

Study design

Prospective, blinded, multicenter study.

The blinded data will be evaluated and monitored externally.

An interim analysis to assess signal quality will be performed after inclusion of 50% of the planned subjects. If there are <10% non-evaluable signals, the number of subjects will be adjusted accordingly. The aim is to enroll 600 evaluable subjects.

Methods

The subjects will be asked to place a smartwatch on each arm to allow their pulse curve to be recorded for five minutes. At the same time, an ambulatory ECG system will take a synchronous ECG for reference. The ECG system employed is equipped with a validated automatic atrial fibrillation detector, used as a reference for assignment to groups. Data will be collected on person-related information, comorbidities and medication (estimated overall duration/patient <20 min). No follow-up is planned. Analogous to predecessor studies, the pulse wave curve data are coded with the patient's identification number (ID) and externally analyzed at Preventicus; based on the results, the patients will be assigned to SR/AF groups. After evaluation of all files, the grouped results will be aggregated, unblinded and evaluated under monitoring.

Primary target parameters are the app's sensitivity and specificity in correctly detecting atrial fibrillation compared to an automatically interpreted ECG.

Secondary target parameters include the proportion of non-evaluable recordings in the overall study, differences between the two smartwatches and the app's sensitivity and specificity in patients with >2% premature beats.

Study Design

Study Type:
Observational
Actual Enrollment :
651 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
SmartWATCHes for Detection of Atrial Fibrillation
Study Start Date :
Dec 1, 2016
Actual Primary Completion Date :
Dec 1, 2017
Actual Study Completion Date :
Dec 1, 2017

Arms and Interventions

Arm Intervention/Treatment
AF

Five minutes pulse wave recording in patients with atrial fibrillation at the time of recruitment

Device: Five minutes pulse wave recording
Patients will wear a smart watch and a wristband each at one arm. A standard egg (lead I) and pig signals from the wearables will be recorded for five minutes.

SR

Five minutes pulse wave recording in patients with sinus rhythm at the time of recruitment

Device: Five minutes pulse wave recording
Patients will wear a smart watch and a wristband each at one arm. A standard egg (lead I) and pig signals from the wearables will be recorded for five minutes.

Outcome Measures

Primary Outcome Measures

  1. Correct detection of AF [5 minutes]

    Sensitivity and specificity of the Preventicus Heartbeats App to distinguish between AF and SR

Secondary Outcome Measures

  1. Differences in correct detection of AF between Smartwatch and Wristband [5 minutes]

    Smartwatch and Wristband will be worn simultaneously. As there is no difference in rhythm between left and right lower arm it will be analyzed if there are differences in the primary outcome between the two devices.

  2. Reduced sensitivity and specificity in patients with >2% premature beats [5 minutes]

    Patients in the SR group will be screened for premature beats. The ones with >2% will be taken for an second analysis to validate if the sensitivity of the algorithm is less good for patients with a high number of premature beats.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subjects of legal age,

  • patients with either sinus rhythm (Group SR) or atrial fibrillation (Group AF)

  • signed informed consent form

Exclusion Criteria:
  • Legally incompetent persons

Contacts and Locations

Locations

Site City State Country Postal Code
1 Universitätsmedizin Greifswald, Klinik und Poliklinik für Innere Medizin B Greifswald Germany 17475
2 University Hospital Basel Basel BS Switzerland 4031

Sponsors and Collaborators

  • University Hospital, Basel, Switzerland
  • University Hospital Greifswald

Investigators

  • Principal Investigator: Jens Eckstein, MD, PhD, University Hospital, Basel, Switzerland

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT02956343
Other Study ID Numbers:
  • 2016-01175
First Posted:
Nov 6, 2016
Last Update Posted:
Jan 16, 2018
Last Verified:
Jan 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Keywords provided by University Hospital, Basel, Switzerland
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 16, 2018